II级和III级脑膜瘤的放射外科治疗：系统评价和荟萃分析

Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis.

作者信息

Jahanbakhshi Amin, Najafi Masoumeh, Gomar Marzieh, Ciammella Patrizia, Ruggieri Maria Paola, Iotti Cinzia, Finocchi Ghersi Sebastiano, Serre Anne-Agathe, Bardoscia Lilia, Sardaro Angela, Boisbouvier Sophie, Roukoz Camille, Cozzi Salvatore

机构信息

Skull Base Research Center, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran 1997667665, Iran.

Radiation Oncology Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran 1997667665, Iran.

出版信息

J Pers Med. 2024 Jul 29;14(8):802. doi: 10.3390/jpm14080802.

DOI:10.3390/jpm14080802

PMID:39201994

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11355310/

Abstract

BACKGROUND

Meningiomas are the most prevalent benign intracranial tumors. When they are of the invasive subtypes, i.e., grades II and III, they can recur rapidly and present a real challenge for physicians. This study is focused on the use of stereotactic radiosurgery to manage high-grade meningiomas.

METHOD

Medline via PubMed was searched from inception to December 2022 to retrieve studies on stereotactic radiation therapy for patients with grade II-III meningiomas. This study was conducted under PRISMA guidelines.

RESULT

A total of 29 articles involving 1446 patients with grade II-III meningiomas treated with stereotactic radiation therapy were included in the present study. Of these studies, 11 were conducted exclusively on patients with atypical meningiomas (grade II), 1 targeted anaplastic meningiomas (grade III), and 17 articles were carried out on both grade II and III meningiomas. The pooled 1, 2, 3, 5, and 10-year overall survival (OS) of grade II meningiomas was 0.96 [ < 0.01], 0.89 [ = 0.01], 0.90 [ = 0.09], 0.81 [ < 0.01], and 0.66 [ = 0.55], respectively. The pooled 2, 5, and 10-year OS of grade III meningiomas was 0.64 [ = 0.01], 0.41 [ = 0.01], and 0.19 [ < 0.01], respectively.

CONCLUSIONS

Although long-term prospective studies are still required, the outcomes of stereotactic radiation therapy appear promising regarding overall outcome and progression-free survival.

摘要

背景

脑膜瘤是最常见的颅内良性肿瘤。当它们属于侵袭性亚型，即II级和III级时，可能会迅速复发，给医生带来真正的挑战。本研究聚焦于使用立体定向放射外科治疗高级别脑膜瘤。

方法

通过PubMed检索Medline数据库，从建库至2022年12月，以获取关于II - III级脑膜瘤患者立体定向放射治疗的研究。本研究按照PRISMA指南进行。

结果

本研究共纳入29篇文章，涉及1446例接受立体定向放射治疗的II - III级脑膜瘤患者。在这些研究中，11项仅针对非典型脑膜瘤（II级）患者进行，1项针对间变性脑膜瘤（III级），17篇文章同时涉及II级和III级脑膜瘤。II级脑膜瘤的1年、2年、3年、5年和10年总生存率（OS）分别为0.96[<0.01]、0.89[=0.01]、0.90[=0.09]、0.81[<0.01]和0.66[=0.55]。III级脑膜瘤的2年、5年和10年总生存率分别为0.64[=0.01]、0.41[=0.01]和0.19[<0.01]。